An interventional study of Radiesse injectable implant (dermal filler) and Restylane injectable implant (dermal filler) in Correction of the Moderate to Severe Nasolabial Folds, sponsored by Merz North America, Inc.. Completed at 4 sites in China. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-23.
Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are to evaluate the effectiveness and safety of Radiesse for the correction of nasolabial folds (NLFs).
Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has received within the specified (washout) period or plans to receive treatment during the study conduct with a non-permanent facial filler in any facial area below the eyes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.
Device: Radiesse injectable implant (dermal filler) · Device: Restylane injectable implant (dermal filler)
Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.
Device: Radiesse injectable implant (dermal filler) · Device: Restylane injectable implant (dermal filler)
Subdermal injection.
Also known as: Calcium hydroxylapatite particles suspected in an aqueous based gel carrier.
Subdermal injection
Also known as: Hyaluronic acid
Percentage of NLFs With Treatment Success at Month 6
Treatment success was defined as a greater than or equal to (\>=) 1-point improvement from baseline, as assessed by a blinded evaluator wrinkle severity rating scale (WSRS) scale. WSRS is a 5 point scale with scores as Score 1: Absent; Score 2: Mild; Score 3: Moderate; Score 4: Severe; Score 5: Extreme.
Time frame: Month 6
Percentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 6
The blinded evaluator rated the current cosmetic result for each NLF according to the GAIS based on live assessments during the visit compared with photographs taken at baseline before administration of treatment on each NLF. An improvement on the GAIS was classified as "improved", "much improved", or "very much improved. The GAIS is a 7-point scale, where: +3 (very much improved), +2 (much improved), +1 (improved), 0 (no change), -1 (worse), -2 (much worse), and -3 (very much worse).
Time frame: Month 6
The study was conducted at 4 investigative sites in China.
| Milestone | Radiesse and Restylane |
|---|---|
| Started | 181 |
| Safety evaluation set | 176 |
| Completed | 164 |
| Not completed | 17 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Other | 9 |
Treatment success was defined as a greater than or equal to (\>=) 1-point improvement from baseline, as assessed by a blinded evaluator wrinkle severity rating scale (WSRS) scale. WSRS is a 5 point scale with scores as Score 1: Absent; Score 2: Mild; Score 3: Moderate; Score 4: Severe; Score 5: Extreme.
| Percentage of successfully treated NFLs | Radiesse | Restylane |
|---|---|---|
| Percentage of NLFs With Treatment Success at Month 6 | 66.0 | 72.8 |
The blinded evaluator rated the current cosmetic result for each NLF according to the GAIS based on live assessments during the visit compared with photographs taken at baseline before administration of treatment on each NLF. An improvement on the GAIS was classified as "improved", "much improved", or "very much improved. The GAIS is a 7-point scale, where: +3 (very much improved), +2 (much improved), +1 (improved), 0 (no change), -1 (worse), -2 (much worse), and -3 (very much worse).
| Percentage of NLFs | Radiesse | Restylane |
|---|---|---|
| Percentage of NLFs With an Improvement in the Blinded Evaluator's GAIS Score at Month 6 | 78.4 | 83.3 |
Collected over Baseline up to Month 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Radiesse and Restylane | 0/176 (0%) | 4/176 (2.3%) | 56/176 (31.8%) |
| Event | Radiesse and Restylane |
|---|---|
| Cervical dysplasiaReproductive system and breast disorders | 1/176 |
| Endometrial thickeningReproductive system and breast disorders | 1/176 |
| Uterine haemorrhageReproductive system and breast disorders | 1/176 |
| Chest discomfortGeneral disorders | 1/176 |
| Chest painGeneral disorders | 1/176 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/176 |
| Event | Radiesse and Restylane |
|---|---|
| Urinary tract infectionInfections and infestations | 16/176 |
| Injection site noduleGeneral disorders | 14/176 |
| Upper respiratory tract infectionInfections and infestations | 11/176 |
| HyperlipidaemiaMetabolism and nutrition disorders | 11/176 |
| Viral upper respiratory tract infectionInfections and infestations | 10/176 |
The safety evaluation set (SES) was defined as all participants who received an investigational product.
| Age, Continuous(years) | Radiesse and Restylane |
|---|---|
| Mean | 45.6 ± 9.43 |
| Sex: Female, Male(Participants) | Radiesse and Restylane |
|---|---|
| Female | 170 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Radiesse and Restylane |
|---|---|
| Ethnicity — Han Chinese | 173 |
| Ethnicity — Other | 3 |
| Race/Ethnicity, Customized(Participants) | Radiesse and Restylane |
|---|---|
| Race (Asian) | 176 |
| Region of Enrollment(Participants) | Radiesse and Restylane |
|---|---|
| China | 176 |
| Fitzpatrick skin type(Participants) | Radiesse and Restylane |
|---|---|
| Type I | 0 |
| Type II | 0 |
| Type III | 147 |
| Type IV | 29 |
| Type V | 0 |
| Type VI | 0 |
| Missing | 0 |
| Height(centimeter (cm)) | Radiesse and Restylane |
|---|---|
| Mean | 159.9 ± 5.60 |
| Weight(kilogram (Kg)) | Radiesse and Restylane |
|---|---|
| Mean | 56.15 ± 8.434 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Jul 2018, 11 months.
Results were first posted in Feb 2021, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.